Company: IMCR
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001671927-25-000006
Chunk: 20

Company: Immunocore Holdings plc
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 20
---
ated Statements of Shareholders’ Equity

(in thousands, except share data)

Ordinary SharesDeferredSharesAccumulatedDeficit AccumulatedOtherComprehensive(Loss)Income TotalShareholders’Equity SharesAmountSharesAmountAdditionalPaid-in CapitalAt January 1, 202243,862,850$118 5,793,501$1 $900,745 $(636,844)$(30,315)$233,705 Net loss—— —— — (52,543)— (52,543)Other comprehensive loss—— —— — — (24,358)(24,358)Issuance of ordinary shares, net3,733,33310 —— 139,505 — — 139,515 Exercise of share options492,1631 —— 9,695 — — 9,696 Share-based compensation expense—— —— 32,888 — — 32,888 At December 31, 202248,088,346$129 5,793,501$1 $1,082,833 $(689,387)$(54,673)$338,903 Net loss—— —— — (55,287)— (55,287)Other comprehensive income—— —— — — 18,412 18,412 Exercise of share options1,637,3035 —— 34,341 — — 34,346 Share-based compensation expense—— —— 32,469 — — 32,469 At December 31, 202349,725,649$134 5,793,501$1 $1,149,643 $(744,674)$(36,261)$368,843 Net loss—— —— — (51,087)— (51,087)Other comprehensive income—— —— — — 2,498 2,498 Exercise of share options339,2111 —— 6,265 — — 6,266 Share-based compensation expense—— —— 34,196 — — 34,196 At December 31, 202450,064,860$135 5,793,501$1 $1,190,104 $(795,761)$(33,763)$360,716 

The accompanying notes form an integral part of these consolidated financial statements.

F